BBO-8520

KRASG12C dual inhibitor for KRAS cancers

estimated prevalence

40,000

Disease

KRAS+ cancers

Genetic Source

KRAS

Clinical Phase

Pre-clinical

Modality

small molecule

our science

our science icon icon

our approach icon icon

patient resources icon icon